Blue Jet Healthcare reported a sharp 40% YoY decline in Q3 FY26 revenue to ₹192.4 crore, with EBITDA down 62% and PAT down 39%, driven by destocking in the key pharma intermedia...
Financial stats pending filing verification
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Management acknowledged destocking and supply chain realignment for bempedoic acid, but did not quantify the impact or confirm when volumes will normalize. Analyst raised concern about potential permanent loss of market share.
high · analyst_questionGross margin fell to 52% in Q3 due to product mix and a 1% inventory write-off. Management guided a wide 50-55% range, indicating uncertainty.
medium · data_observationDespite diversification efforts, a significant portion of revenue still depends on a few molecules, making the company vulnerable to order lumpiness.
medium · analyst_questionThe large greenfield capex may strain cash flows; management mentioned options including debt or equity dilution, but no firm plan was provided.
medium · analyst_question